All News

Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.

Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.

Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.

Julie M. Vose, MD, MBA, reviews the rising cancer diagnoses that are estimated to impact 2 million people in 2024.

Data from the interim analysis of the ACCENT trial showed promising signs of efficacy with narmafotinib combination therapy in advanced pancreatic cancer.

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

Ruxolitinib, currently approved as treatment for patients with myelofibrosis and polycythemia vera, is currently undergoing evaluation in myeloma studies.

Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.

Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.

Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.

Pelareorep plus paclitaxel improved the overall response rate vs paclitaxel monotherapy among patients in the phase 2 BRACELET-1 study.

Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.

Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

A belantamab mafodotin combination regimen has been accepted for review in Japan, based on data from the DREAMM-7 and DREAMM-8 clinical trials.

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.

ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.

Deep and durable responses were observed with lenvatinib plus pembrolizumab in patients with stage III/IV recurrent endometrial carcinoma.

DFS was improved with 1-year trastuzumab in patients with ERBB2-positive breast cancer enrolled in the SOLD trial.

Data from the KEYNOTE-483 trial support the FDA approval of the pembrolizumab-based combination in this pleural mesothelioma population.

Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.

Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.

HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.

Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.

Data from the SunRISe-4 trial demonstrate the benefit of adding TAR-200 to checkpoint inhibition among patients with muscle-invasive bladder cancer.

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.

Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.

Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Thomas Powles, MBBS, MRCP, MD, presented results from the NIAGRA trial assessing perioperative durvalumab in patients with cisplatin-eligible MIBC.